In patients with mild/moderate to severe COVID-19, due to high prevalence of HLA-C*04:01, these effects provide a decrease of the HLA class I loci heterozygosity and a down-modulation of the predicted HLA class I ability to recognize SARS-CoV-2 peptides. The gene discussed is HLA-C; the disease is COVID-19.